Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EBITDA (2018 - 2025)

Inmune Bio's EBITDA history spans 8 years, with the latest figure at -$6.5 million for Q3 2025.

  • For Q3 2025, EBITDA rose 47.87% year-over-year to -$6.5 million; the TTM value through Sep 2025 reached -$49.6 million, down 19.34%, while the annual FY2024 figure was -$41.9 million, 39.03% down from the prior year.
  • EBITDA for Q3 2025 was -$6.5 million at Inmune Bio, up from -$24.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$4.6 million in Q1 2021 and bottomed at -$24.6 million in Q2 2025.
  • The 5-year median for EBITDA is -$8.5 million (2023), against an average of -$9.0 million.
  • The largest annual shift saw EBITDA crashed 224.74% in 2021 before it surged 47.87% in 2025.
  • A 5-year view of EBITDA shows it stood at -$9.6 million in 2021, then surged by 43.57% to -$5.4 million in 2022, then plummeted by 57.18% to -$8.5 million in 2023, then dropped by 3.36% to -$8.8 million in 2024, then grew by 26.08% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's EBITDA are -$6.5 million (Q3 2025), -$24.6 million (Q2 2025), and -$9.8 million (Q1 2025).